PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media276477ArticlesСтатьиrole of sotalol in the treatment of heart rhythm disturbances: modern approachesРОЛЬ СОТАЛОЛА В ЛЕЧЕНИИ НАРУШЕНИЙ СЕРДЕЧНОГО РИТМА: СОВРЕМЕННЫЕ ПОДХОДЫSulimovV AСулимовВ А

ММА им. И.М. Сеченова, Москва

NapalkovD AНапалковД А

ММА им. И.М. Сеченова, Москва

SulimovV ANapalkovD AММА им. И.М. Сеченова, Москва20032009166NO6 (2009)№6 (2009)162122022023Copyright ©; 2009, Bionika MediaCopyright ©; 2009, ООО «Бионика Медиа»2009Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/276477

Sotalol is a mixture of sinistrorotatory (has the properties of beta-blocker, increases the duration of the action potential of cardiomyocytes) and dextrorotatory (characterized by the properties of class III antiarrhythmics) stereoisomers. Several studies showed sotalol efficacy for reduction of atrial fibrillation and maintenance of sinus rhythm, comparable to amiodarone. In long-term monitoring, sotalol is less effective than amiodarone, but has a better safety profile. In addition, sotalol and amiodarone are major antiarrhythmics applied for the secondary prevention of sudden cardiac death.

Соталол представляет собой смесь левовращающего (обладает свойствами бета-адреноблокатора, увеличивает продолжительность потенциала действия кардиомиоцитов) и правовращающего (характеризуется свойствами антиаритмиков III класса) стереоизомеров. В ряде исследований соталол показал эффективность в отношении устранения фибрилляции предсердий и сохранения синусового ритма, сопоставимую с таковой амиодарона. При долгосрочном наблюдении соталол несколько уступает амиодарону, но имеет при этом лучший профиль безопасности. Кроме того, соталол, как и амиодарон, является основным антиаритмиком, применяющимся для вторичной профилактики внезапной сердечной смерти.

cardiac arrhythmiaatrial fibrillationsudden deathsotalolamiodaroneаритмии сердцафибрилляция предсердийвнезапная смертьсоталоламиодаронШубик Ю.В., Чирейкин Л.В. Соталол в лечении аритмий // В помощь практическому врачу. 1998. № 10. С. 80-83.Сулимов В.А., Гиляров М.Ю. Современные стратегии медикаментозной терапии фибрилляции предсердий // Фарматека. 2002. № 7-8. С. 49-59.Camm AJ, Savelieva I, Lip GY. Rate control in the medical management of atrial fibrillation. Heart 2007;93:35-38.Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.Jahangiri M, Weir G, Mandal K, et al. Current strategies in the management of atrial fibrillation. Ann Thorac Surg 2006;82:357-64.Savelieva I, Camm J. Anti-arrhythmic therapy for atrial fibrillation: current anti-arrhythmic drug, investigational agents and innovative approaches. Europace 2008;10(6):647-65.Fetch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004;25(16):1385-94.Singh BN, Singh SN, Reda DJ, et al., Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.Niu F, Huang CX, Jiang H, et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. -Zhonghua Yi Xue Za Zhi 2006;86(2):12123 <http://www.medscape.com/medline/publicationbrowser/123?pmid=16620720>.Mooss AN, Wurdeman RL, Sugimoto JT, et al. Amiodarone Versus Sotalol for the Treatment of Atrial Fibrillation After Open Heart Surgery: The Reduction in Postoperative Cardiovascular Arrhythmic Events (REDUCE) Trial. Am Heart J 2004;148(4):641-48.Ali S, Antezano ES. Sudden Cardiac Death. South Med J 2006;99(5):502-10.Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987;113:799-804.Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.Julian DG, Prescott RG, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1(8282):1142-47.Pitt B, White H, Nicolau J, et al. Eplerenone reduced mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31.Nanthakumar K, Epstein AE, Kay NG, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2004;44:2166-72.Pavia S, Wilkoff B. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Curr Opin Cardiol 2001;16:66-71.Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 2004;109:1503-08.Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (Pain FREE Rx II) trial. Circulation 2005;111:2898-905.Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-65.DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med 2003;349:1836-1847.Mason JW. A comparison of seven antiarrythmic drugs in patients with ventricular tachyarrythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring investigators. N Engl J Med 1993;329(7):452-58.Watanabe H, Chinushi M, Washizuka T, et al. Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias. -Pacing Clin Electrophysiol 2005;28(4):28590 <http://www.medscape.com/medline/publicationbrowser/123?pmid=15826260>.Furushima H, Chinushi M, Okamura K, et al. Effect of dl-sotalol on mortality and recurrence of ventricular tachyarrhythmias: ischemic compared to nonischemic cardiomyopathy. -Pacing Clin Electrophysiol 2007;30(9):113641 <http://www.medscape.com/medline/publicationbrowser/123?pmid=17725758>.Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind, randomized crossover comparative study in the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischemic heart disease. Eur Heart J 2001;22(23):2141-43.Fuster V, Riden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-354.http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2249&mid=1085056570&magid=169&full=1